Invivo Partners

Signadori Bio is a biopharmaceutical company dedicated to developing innovative cellular immunotherapy treatments for cancer. It operates in the cell and gene therapy space, aiming to advance novel approaches in oncology to help doctors combat cancer more effectively.

Founded in 2020, NEUmiRNA focuses on achieving transformative disease modification for neurological conditions.

Gyala Therapeutics specializes in developing innovative CAR-T therapies aimed at treating hematological malignancies. CAR-T (chimeric antigen receptor T cell) therapy involves extracting T lymphocytes from a patient's blood through apheresis, genetically reprogramming these cells to recognize and attack tumor cells, and then reintroducing them into the patient. This approach has shown efficacy in treating leukemias and B cell lymphomas by leveraging the body's immune system to target cancer cells.

EsoBiotec is a Belgian biotechnology company dedicated to the discovery of innovative cancer therapies. The firm specializes in immunotherapies that aim to empower the human body to combat cancer through in vivo cell engineering. EsoBiotec focuses on developing cost-effective drugs and therapeutics, ensuring that patients have access to essential cancer treatments at lower costs. By prioritizing accessibility, the company seeks to improve the overall effectiveness of cancer care and enhance patient outcomes.

Corteria Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for heart failure subpopulations, particularly focusing on acute decompensated heart failure. The company aims to address unmet medical needs by creating first-in-class drugs that enhance the understanding of disease biology among medical professionals. In addition to heart failure, Corteria also explores treatments for related conditions, such as sarcopenia and obesity, to improve patient outcomes and provide effective solutions for complex health issues. Through its research and development efforts, Corteria Pharmaceuticals seeks to transform the landscape of heart failure treatment.

OneChain Immunotherapeutics is a spin-off Company from Instituto de Investigación contra la Leucemia Josep Carreras and ICREA, that aims to develop CAR-T candidates against different antigens as a treatment for hematological malignancies based on the know-how of Dr. Pablo Menéndez.

Arthex Biotech S.L. is a biotechnology company founded in 2019 and based in Paterna, Spain. It specializes in the development of antisense RNA treatments specifically aimed at addressing genetic diseases and disorders where microRNAs play a significant role. As a spin-off from the University of Valencia, Arthex Biotech leverages a strong foundation in drug discovery and has a team comprising experts with extensive experience in neuromuscular diseases. The company focuses on creating innovative therapies for conditions with unmet medical needs, providing new treatment options for patients suffering from rare genetic diseases and other high-need medical issues. With guidance from esteemed scientific and clinical advisors, Arthex Biotech is committed to advancing its product development to improve patient outcomes.

Atekka is an insurance company focused on providing protection against agricultural risks. By integrating technical and technological innovations, Atekka develops customized agricultural insurance products in collaboration with cooperatives and farmers. The company aims to support the agricultural sector by enabling farmers to safeguard their operations from various calamities, thereby enhancing their resilience and sustainability in the face of challenges.

Corteria Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for heart failure subpopulations, particularly focusing on acute decompensated heart failure. The company aims to address unmet medical needs by creating first-in-class drugs that enhance the understanding of disease biology among medical professionals. In addition to heart failure, Corteria also explores treatments for related conditions, such as sarcopenia and obesity, to improve patient outcomes and provide effective solutions for complex health issues. Through its research and development efforts, Corteria Pharmaceuticals seeks to transform the landscape of heart failure treatment.

Integra Therapeutics is a biotechnology company focused on advancing gene editing technologies to address various diseases. It develops innovative gene writing tools that enhance the capabilities of gene therapy, aiming to meet the specific needs of patients. By integrating the precision of CRISPR systems with the efficiency of viral integrases and transposases, Integra Therapeutics seeks to overcome existing limitations in gene editing. The company's approach enables scientists to introduce DNA into genomes using sequence-specific DNA binding proteins, facilitating the development of more effective gene therapies.

Telomere Therapeutics is a biotechnology company focused on developing gene therapies that target age-related diseases through the expression of the telomerase gene, specifically TERT. The company's innovative approach utilizes an adenoviral-associated vector to deliver this therapy, aiming to address conditions such as idiopathic pulmonary fibrosis, aplastic anemia, and dyskeratosis congenita. By harnessing the potential of telomerase gene therapy, Telomere Therapeutics seeks to provide effective treatment options for prevalent age-related ailments, thereby improving patient outcomes and quality of life.

MiiMOSA is a crowdfunding platform focused on the agriculture and food sectors. It provides an alternative financing solution for project developers seeking quick and straightforward funding from a community of contributors. The platform allows users to create customized fundraising projects while enabling the public to financially support initiatives that resonate with them. In addition to monetary contributions, MiiMOSA offers unique donation options, including products like cheese, yogurt, whiskey, and ice cream, enhancing the engagement between project developers and supporters. This approach fosters a collaborative environment aimed at revitalizing the agriculture industry and promoting sustainable food practices.

Telomere Therapeutics is a biotechnology company focused on developing gene therapies that target age-related diseases through the expression of the telomerase gene, specifically TERT. The company's innovative approach utilizes an adenoviral-associated vector to deliver this therapy, aiming to address conditions such as idiopathic pulmonary fibrosis, aplastic anemia, and dyskeratosis congenita. By harnessing the potential of telomerase gene therapy, Telomere Therapeutics seeks to provide effective treatment options for prevalent age-related ailments, thereby improving patient outcomes and quality of life.

OneChain Immunotherapeutics is a spin-off Company from Instituto de Investigación contra la Leucemia Josep Carreras and ICREA, that aims to develop CAR-T candidates against different antigens as a treatment for hematological malignancies based on the know-how of Dr. Pablo Menéndez.

Arthex Biotech S.L. is a biotechnology company founded in 2019 and based in Paterna, Spain. It specializes in the development of antisense RNA treatments specifically aimed at addressing genetic diseases and disorders where microRNAs play a significant role. As a spin-off from the University of Valencia, Arthex Biotech leverages a strong foundation in drug discovery and has a team comprising experts with extensive experience in neuromuscular diseases. The company focuses on creating innovative therapies for conditions with unmet medical needs, providing new treatment options for patients suffering from rare genetic diseases and other high-need medical issues. With guidance from esteemed scientific and clinical advisors, Arthex Biotech is committed to advancing its product development to improve patient outcomes.

Telum Therapeutics is a biotechnology company focused on developing novel treatments for infectious diseases. It specializes in harnessing lytic enzymes derived from bacteriophages, offering an alternative to traditional chemical antibiotics, particularly effective against multi-drug resistant bacteria due to their unique, rapid mode of action and immutable targets.

Gyala Therapeutics specializes in developing innovative CAR-T therapies aimed at treating hematological malignancies. CAR-T (chimeric antigen receptor T cell) therapy involves extracting T lymphocytes from a patient's blood through apheresis, genetically reprogramming these cells to recognize and attack tumor cells, and then reintroducing them into the patient. This approach has shown efficacy in treating leukemias and B cell lymphomas by leveraging the body's immune system to target cancer cells.

Pulmobiotics is a pre-clinical life sciences company based in Barcelona, Spain, focused on developing innovative treatments and vaccines for lung diseases. Utilizing synthetic biology, the company aims to create novel antigens and vaccines specifically designed to address various human lung illnesses. Pulmobiotics has developed attenuated lung bacteria that can expose antigens or deliver therapeutic agents directly within the lungs in a controlled and continuous manner. This targeted approach allows for the precise delivery of treatments, enabling patients to address and potentially heal their breathing-related issues effectively.

Arthex Biotech S.L. is a biotechnology company founded in 2019 and based in Paterna, Spain. It specializes in the development of antisense RNA treatments specifically aimed at addressing genetic diseases and disorders where microRNAs play a significant role. As a spin-off from the University of Valencia, Arthex Biotech leverages a strong foundation in drug discovery and has a team comprising experts with extensive experience in neuromuscular diseases. The company focuses on creating innovative therapies for conditions with unmet medical needs, providing new treatment options for patients suffering from rare genetic diseases and other high-need medical issues. With guidance from esteemed scientific and clinical advisors, Arthex Biotech is committed to advancing its product development to improve patient outcomes.